相关实验视频

Updated: May 5, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

甲托雷克萨特和低剂量普得尼松在异常性逆肌纤维化:一个随机临床试验

Francesco Peyronel¹, Alessandra Palmisano², Federica Maritati³

¹Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Firenze, Italy; Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.

Journal of autoimmunity

|September 20, 2025

概括

甲托雷克萨特加低剂量普得尼松与标准剂量普得尼松在异形逆肌纤维化缓解方面同样有效. 这种组合疗法显著降低了患者对葡萄糖皮质激素的暴露,改善了安全性.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
类风湿病学类风湿病学
免疫学免疫学免疫学

背景情况:

异常性逆肌纤维化 (RPF) 是一种罕见的疾病,其特征是逆肌的炎症和纤维化.
葡萄糖皮质类药物是标准治疗方法,但与显著的长期毒性有关.
需要采用替代治疗策略,以减少类固醇暴露,同时保持疗效.

研究的目的:

在新诊断的异常性RPF患者中,评估结合甲状腺素与低剂量普得尼松相比,单独使用标准剂量的普得尼松的疗效和安全性.
为了确定组合疗法在实现缓解方面是否与标准治疗相比不劣.
评估对降低葡萄糖皮质体剂量和治疗相关毒性的影响.

主要方法:

进行了一项开放的,随机的,主控的,非劣势的III期试验.
60名患有异常性RPF的成年患者被招募并随机 (1:1) 接受甲状腺素加低剂量普得尼松 (MTX + LowPred) 或单独标准剂量普得尼松 (standPred) 治疗9个月.
主要终点是第9个月缓解,定义为没有症状,没有尿道阻塞,以及正常的急性阶段反应物. 二级终点包括RPF厚度的减少,复发率和毒性.

主要成果:

29名患者接受了MTX+LowPred,31名患者接受了standPred.
第9个月的缓解率为MTX + LowPred的89.7%,StandPred的80.6%,符合非劣势标准 (差异9.1%,95%CI -9.9%至27.3%).
缓解的时间,RPF厚度的减少和复发率在各组之间是可比的. MTX + LowPred 组的累计普得尼松剂量中位数明显较低. 不良事件是相似的.

结论:

低剂量普得尼松加上甲铁酸的治疗方案对于在异常性逆肌纤维化中实现缓解,与标准剂量普得尼松无差.
与标准治疗相比,这种联合治疗可以显著减少葡萄糖皮质激素暴露.
甲托雷克萨特加上低剂量普得尼松是一种可行的,可能更安全的治疗选择,用于异常性RPF.

关键词:

在IgG4的基础上,IgG4 甲基甲酸二醇的使用方法在耳周炎 (periaortitis)普雷尼索尼 (Prednisone) 是一种药物.逆上皮质纤维化逆上皮质纤维化

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...